Sii Investments Inc. WI Has $1,472,000 Position in Novo Nordisk A/S (NVO)

Sii Investments Inc. WI cut its position in Novo Nordisk A/S (NYSE:NVO) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,053 shares of the company’s stock after selling 2,234 shares during the period. Sii Investments Inc. WI’s holdings in Novo Nordisk A/S were worth $1,472,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ngam Advisors L.P. increased its position in Novo Nordisk A/S by 2.1% in the second quarter. Ngam Advisors L.P. now owns 902,947 shares of the company’s stock worth $48,561,000 after buying an additional 18,189 shares during the period. Morgan Stanley increased its position in Novo Nordisk A/S by 88.6% in the third quarter. Morgan Stanley now owns 3,012,074 shares of the company’s stock worth $125,273,000 after buying an additional 1,415,016 shares during the period. JPMorgan Chase & Co. increased its position in Novo Nordisk A/S by 124.1% in the third quarter. JPMorgan Chase & Co. now owns 1,156,876 shares of the company’s stock worth $48,115,000 after buying an additional 640,540 shares during the period. Grimes & Company Inc. purchased a new position in Novo Nordisk A/S during the third quarter worth about $8,000,000. Finally, Airain ltd purchased a new position in Novo Nordisk A/S during the third quarter worth about $4,718,000. Hedge funds and other institutional investors own 6.65% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Shares of Novo Nordisk A/S (NYSE:NVO) traded down 0.2393% during trading on Friday, reaching $35.3552. The company had a trading volume of 1,017,554 shares. The stock has a market capitalization of $88.54 billion, a price-to-earnings ratio of 16.4903 and a beta of 0.83. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $57.81. The company’s 50 day moving average is $35.34 and its 200-day moving average is $39.44.

The firm also recently declared an annual dividend, which will be paid on Tuesday, April 4th. Stockholders of record on Monday, March 27th will be given a dividend of $0.6634 per share. This represents a dividend yield of 1.99%. The ex-dividend date is Thursday, March 23rd. Novo Nordisk A/S’s payout ratio is presently 46.19%.

This report was posted by Web Breaking News and is owned by of Web Breaking News. If you are accessing this report on another domain, it was stolen and republished in violation of international trademark and copyright laws. The correct version of this report can be read at http://www.webbreakingnews.com/2017/02/17/sii-investments-inc-wi-has-1472000-position-in-novo-nordisk-as-nvo.html.

NVO has been the topic of a number of recent research reports. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, January 31st. TheStreet cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday, November 11th. Citigroup Inc. cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Monday, October 31st. Credit Suisse Group reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, December 1st. Finally, DNB Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, October 31st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. Novo Nordisk A/S has an average rating of “Hold” and an average price target of $60.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.